Startseite

Prof. Dr. Franziska Richter Assencio

zurück zur Übersicht

Prof. Dr. Franziska Richter Assêncio

Kandidatin Sektionssprecherin  "Neuropharmakologie/-toxikologie"

Direktorin, Institut für Pharmakologie, Toxikologie und Pharmazie,
Stiftung Tierärztliche Hochschule Hannover
Buenteweg 17
30559 Hannover

Tel:  (+49) 0511 953 8720
Fax: (+49) 0511 953 8581

E-Mail: franziska.richter@tiho-hannover.de
Website: https://www.tiho-hannover.de/kliniken-institute/institute/institut-fuer-pharmakol...

Curriculum Vitae

  
Geburtsdatum: 27.6.1979 in Berlin
Familienstand: verheiratet, 2 Kinder

Werdegang

seit 2019 Univ.-Professorin (W3), Direktorin, Institut für Pharmakologie, Toxikologie und Pharmazie, Stiftung Tierärztliche Hochschule Hannover
2017 Habilitation in Pharmakologie und Toxikologie an der Veterinärmedizinischen Fakultät der Universität Leipzig und Abschluss zur Fachtierärztin für Pharmakologie und Toxikologie
2012-2019 Wissenschaftliche Mitarbeiterin, Privatdozentin, Institut für Pharmakologie, Pharmazie und Toxikologie, Veterinärmedizinische Fakultät der Universität Leipzig
2009-2012 Assistant Researcher (Faculty, Professional Research Series)
University of California Los Angeles (UCLA, USA), David Geffen School of Medicine, Department of Neurology
2007-2009 Postdoctoral Scholar als Feodor-Lynen-Fellow der Alexander von Humboldt Foundation, University of California Los Angeles (UCLA, USA), David Geffen School of Medicine, Department of Neurology, Laboratory of Prof. Dr. Marie-Francoise Chesselet
2007 Postdoc (Deutsche Forschungsgemeinschaft), Institut für Pharmakologie und Toxikologie, Fachbereich Veterinärmedizin, Freie Universität Berlin
2004-2007 Promotion (Berlin excellence program, NaFöG), Institut für Pharmakologie und Toxikologie, Fachbereich Veterinärmedizin, Freie Universität Berlin, Dissertation in Neuropharmakologie mit Abschluss “summa cum laude”
1998-2003 Studium der Veterinärmedizin, Fachbereich Veterinärmedizin, Freie Universität Berlin, Abschluss Staatsexamen

 

Ausgewählte Auszeichnungen und Aktivitäten

seit 2026

 Spokesperson, Research Integration Unit VENOM (Neuroinfection), University of Veterinary Medicine Hannover
seit 2025 Board Member and Equal Opportunities Spokesperson, DFG Collaborative Research Centre 1270 ELAINE
seit 2024 Elected Chair of the Board, Center for Systems Neuroscience Hannover, comprising 58 neuroscience research groups across four universities
seit 2023 Spokesperson, Neuropharmacology/Toxicology Section and Board Member German Neuroscience Society (NWG)
seit 2023 Student-elected Liaison Professor (Vertrauensdozentin)
2022 und 2023     Best Teacher of the Year in Clinical Subjects, elected by students
2021 “Professor of the Year,” second prize nationwide in Medicine and Natural Sciences, awarded by the UNICUM Foundation and federal ministries.
seit 2020 Chair of the Equal Opportunities Commission and Founding Member of the Diversity Commission, University of Veterinary Medicine Hannover
seit 2020 Vice Chair, PhD Programme in Systems Neuroscience, jointly offered by the University of Veterinary Medicine Hannover, Hannover Medical School, Leibniz University Hannover, and Hannover University of Music, Drama and Media
seit 2019 Associate Editor, Naunyn-Schmiedeberg’s Archives of Pharmacology
2012–2019 Animal Welfare Officer, Faculty of Veterinary Medicine, Leipzig University, and Max Planck Institute for Evolutionary Anthropology, Leipzig
2016 Minerva Short-Term Research Award for a research visit to the Weizmann Institute of Science, Israel
2007–2009 Feodor Lynen Postdoctoral Fellowship, Alexander von Humboldt Foundation
2004–2006 Graduate Fellowship, Berlin Excellence Programme (NaFöG)


 

Forschungsgebiete

My research focuses on developing disease-modifying therapies for neurological disorders caused by neurodegeneration, particularly proteinopathies and synucleinopathies, or neuronal dysfunction, such as dystonia. We characterize animal models and investigate disease mechanisms to identify novel therapeutic targets, followed by pre-clinical drug studies. Specific interests include infectious agents as triggers of proteinopathies in the peripheral and central nervous systems; the prion-like spread of α-synuclein pathology; interactions between the peripheral immune and nervous systems; and molecular pathways underlying sex differences.
 

Ausgewählte Publikationen

  1. Lau K, Outeiro TF, Richter F. Rodent models and accompanying in vitro strategies for studying the etiology and therapy of Parkinson’s disease. Journal of Parkinson’s Disease. 2026;16(6):1074–1093. doi:10.1177/1877718X261463389
  2. Baldauf L, Feja M, Stanojlovic M, Strowig T, Visscher C, Schaeffer E, Berg D, Hankel J, Richter F. Depending on intensity, exercise improved or worsened pathology in a model of prodromal Parkinson’s disease. npj Parkinson’s Disease. 2025;11:335. doi:10.1038/s41531-025-01200-y
  3. Feja M, Drath I, Weiß S, Ewe A, Gericke B, Outeiro TF, Stefanis L, Aigner A, Richter F. Nose-to-brain siRNA delivery by PEI/PPI-based nanoparticles reduces α-synuclein expression in a Parkinson’s disease mouse model. Molecular Therapy – Nucleic Acids. 2025;36(3):102671. doi:10.1016/j.omtn.2025.102671
  4. Schreiber CS, Navarro Ramil L, Bieligk J, Meineke R, Rimmelzwaan G, Käufer C, Richter F. Intravenous SARS-CoV-2 Spike protein induces neuroinflammation and alpha-Synuclein accumulation in brain regions relevant to Parkinson’s disease. Brain, Behavior, and Immunity. 2025;129:102–123. doi:10.1016/j.bbi.2025.05.021
  5. Lai TT, Xiang W, Stanojlovic M, Käufer C, Feja M, Lau K, Zunke F, Richter F. The basolateral amygdala and striatum propagate alpha-synuclein pathology causing increased fear response in a Parkinson’s disease model. Brain, Behavior, and Immunity. 2025;128:469–486. doi:10.1016/j.bbi.2025.04.025
  6. Schidlitzki A, Stanojlovic M, Fournier C, Käufer C, Feja M, Gericke B, Garzotti M, Welford RWD, Steiner MA, Angot E, Richter F. Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α-Synuclein. Movement Disorders. 2023;38(6):1044–1055. doi:10.1002/mds.29398
  7. Käufer C, Schreiber CS, Hartke AS, Denden I, Stanelle-Bertram S, Beck S, Kouassi NM, Beythien G, Becker K, Schreiner T, Schaumburg B, Beineke A, Baumgärtner W, Gabriel G, Richter F. Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model. EBioMedicine. 2022;79:103999. doi:10.1016/j.ebiom.2022.103999
  8. Torres ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C, Baldauf L, Fleming S, Masliah E, Chesselet MF, Fanselow MS, Richter F. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson’s disease. Neurobiology of Disease. 2021;158:105478. doi:10.1016/j.nbd.2021.105478
  9. Helmschrodt C, Höbel S, Schöniger S, Bauer A, Bonicelli J, Gringmuth M, Fietz SA, Aigner A, Richter A, Richter F. Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease. Molecular Therapy – Nucleic Acids. 2017;9:57–68. doi:10.1016/j.omtn.2017.08.013
  10. Chesselet MF, Richter F. Modelling of Parkinson’s disease in mice. The Lancet Neurology. 2011;10(12):1108–1118. doi:10.1016/S1474-4422(11)70227-7